David Tsay, M.D., was appointed chief medical officer of Counterpart Health, a Clover Health subsidiary, this month. | Clover ...

Company’s affordable, benefit-rich flagship PPO plans now have 4 Star ratingFRANKLIN, Tenn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLOV) (“Clover” or “the Company”) has announced the debut of ...

Analyst Richard Close from Canaccord Genuity maintained a Buy rating on Clover Health Investments (CLOV – Research Report) and keeping ...

Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member ExperienceFRANKLIN, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) ...

A research team has identified a wealth of bioactive compounds in red clover (Trifolium pratense) seeds and their oil, ...

A research team has identified a wealth of bioactive compounds in red clover (Trifolium pratense ) seeds and their oil, ...

Fintel reports that on October 7, 2024, UBS initiated coverage of Clover Health Investments (NasdaqGS:CLOV) with a Neutral ...

Clover Health (CLOV) stock gains and Humana (HUM) stock falls as the Centers for Medicare & Medicaid Services ...

Clover Health Investments shares are trading higher by 4.6% Friday afternoon. The company announced that CMS raised its PPO Medicare Advantage plans' Star rating to 4 Stars for 2025.

On Friday, Clover Health Investments Corp (CLOV) stock saw a modest uptick, ending the day at $4.07 which represents a slight increase of $0.12 or 3.04% from the prior close of $3.95. The stock opened ...